SRPT vs. UTHR, CTLT, RDY, KRTX, BGNE, LEGN, VTRS, ASND, ITCI, and CERE
Should you be buying Sarepta Therapeutics stock or one of its competitors? The main competitors of Sarepta Therapeutics include United Therapeutics (UTHR), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Karuna Therapeutics (KRTX), BeiGene (BGNE), Legend Biotech (LEGN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Intra-Cellular Therapies (ITCI), and Cerevel Therapeutics (CERE). These companies are all part of the "pharmaceutical preparations" industry.
Sarepta Therapeutics (NASDAQ:SRPT) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.
United Therapeutics has a net margin of 42.31% compared to Sarepta Therapeutics' net margin of -43.11%. United Therapeutics' return on equity of 17.72% beat Sarepta Therapeutics' return on equity.
United Therapeutics has higher revenue and earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.
Sarepta Therapeutics received 856 more outperform votes than United Therapeutics when rated by MarketBeat users. Likewise, 75.40% of users gave Sarepta Therapeutics an outperform vote while only 61.66% of users gave United Therapeutics an outperform vote.
In the previous week, United Therapeutics had 1 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 22 mentions for United Therapeutics and 21 mentions for Sarepta Therapeutics. United Therapeutics' average media sentiment score of 0.62 beat Sarepta Therapeutics' score of 0.26 indicating that United Therapeutics is being referred to more favorably in the news media.
Sarepta Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500.
86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 7.4% of Sarepta Therapeutics shares are owned by insiders. Comparatively, 12.5% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Sarepta Therapeutics presently has a consensus price target of $156.60, indicating a potential upside of 21.61%. United Therapeutics has a consensus price target of $294.25, indicating a potential upside of 25.83%. Given United Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe United Therapeutics is more favorable than Sarepta Therapeutics.
Summary
United Therapeutics beats Sarepta Therapeutics on 13 of the 18 factors compared between the two stocks.
Get Sarepta Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sarepta Therapeutics Competitors List
Related Companies and Tools
